Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Winter;14(4):616-32.

Cardiovascular safety profile of currently available diabetic drugs

Komola Azimova  1 , Zinnia San Juan  1 , Debabrata Mukherjee  1
Affiliations
Review

Cardiovascular safety profile of currently available diabetic drugs

Komola Azimova et al. Ochsner J. 2014 Winter.

Abstract

Background: Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes, underscoring the importance of choosing drugs that do not increase cardiovascular risk and reduce the risk of cardiovascular events. Since 2008, the US Food and Drug Administration has recommended that new drugs for type 2 diabetes undergo clinical trials to demonstrate cardiovascular safety in addition to glycemic benefit. In 2012, the European Medicines Agency issued a similar recommendation.

Methods: We searched the PubMed, Cochrane CENTRAL, EMBASE, and CINAHL databases from inception through August 2013 and compiled and reviewed the existing data on the cardiovascular safety profiles of currently available diabetic drugs.

Results: While intensive glycemic control in diabetics has been consistently shown to reduce the risk of microvascular complications, the data on macrovascular risk reduction have not been as clear, and questions have been raised about possible increases in cardiovascular morbidity and mortality.

Conclusion: Careful selection of drug therapy-paying particular attention to cardiovascular safety-is important in optimizing diabetic therapy.

Keywords: Acarbose; biguanides; cardiovascular diseases; diabetes mellitus; dipeptidyl-peptidase 4 inhibitors; drug therapy; dyslipidemias; hypertension; incretins; sulfonylurea compounds.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial or proprietary interest in the subject matter of this article.

References

    1. Centers for Disease Control and Prevention. National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States. Atlanta, GA: U.S: Department of Health and Human Services, Centers for Disease Control and Prevention; 2011; 2011.
    1. Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643–2653. - PMC - PubMed
    1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837–853. Erratum in: Lancet. 1999 Aug 14;354(9178):602. - PubMed
    1. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995 May;28(2):103–117. - PubMed
    1. Duckworth W, Abraira C, Moritz T, et al. VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. N Engl J Med. N Engl J Med. 2009 Sep 3; 2009;360361361(Jan 8)(2)(10)(10):129–139. 1028, 1024–1025. Errata in. 2009 Sep 3. - PubMed

LinkOut - more resources